Which peptides are studied in relation to telogen effluvium?
A research-supply review of the peptide and peptide-adjacent compounds examined in telogen effluvium models, including GLP-1 receptor agonist-associated hair loss and the pathways under investigation.
Telogen effluvium is a non-scarring, diffuse hair-shedding condition in which a disproportionate number of anagen follicles synchronously enter the telogen (resting) phase, producing increased shedding roughly two to three months after a triggering event. In the research literature, the compounds most directly studied in relation to this condition are not classical 'hair peptides' but glucagon-like peptide 1 receptor agonists (GLP-1RAs) and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists, a class of incretin-mimetic peptides used to improve glycaemic control in patients with type 2 diabetes mellitus and, for some agents, to support weight loss [2]. These are peptide-based molecules; the hair-loss signal associated with them has emerged as a pharmacovigilance finding rather than a designed indication [2].
The mechanistic work centres on the glucagon-like peptide 1 receptor (GLP-1R) and its downstream metabolic and follicular-cycle effects, with the GIP receptor engaged by dual agonists [2].
Research Studies
GLP-1 receptor agonists and hair loss safety signals in treated populations
Safety signals concerning a possible link between GLP-1RA therapies and hair loss have been emerging in the USA, and the commentary literature notes that prescription volumes in Europe are increasing, with an expected corresponding rise in reported cases of GLP-1RA-associated hair loss [2]. The pharmacological context and market expansion for these agents are examined alongside the hair-loss reports [2]. This is observational and pharmacovigilance-level evidence; it does not establish causality.
Dual GIP/GLP-1 receptor agonists and the same reporting pattern
Dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists are discussed within the same safety-signal framework as single-target GLP-1RAs [2]. The commentary treats the class together when considering the pharmacological context and the emerging hair-loss reports [2].
Dietary supplement intervention in GLP-1-associated telogen effluvium
A single-center, open-label clinical study is evaluating whether a dietary supplement can reduce hair loss in women with GLP-1-associated telogen effluvium [1]. Participants use the supplement for 120 days, and researchers evaluate hair loss, hair density, and hair growth through clinical assessments, trichogram hair measurements, and participant questionnaires [1]. The population is specifically women with GLP-1-associated telogen effluvium [1].
Trichogram as an outcome measure in telogen effluvium trials
In the registered study above, the trichogram is named as one of the hair measurements used alongside clinical assessment and questionnaires [1]. This places objective hair-cycle measurement alongside patient-reported outcomes in the same protocol [1].
Hair density and hair growth as endpoints
The same study lists hair loss, hair density, and hair growth as the evaluated parameters over the 120-day supplement period [1]. These are the endpoints specified in the registration record [1].
Population specificity: women with GLP-1-associated telogen effluvium
The registered trial is restricted to women with GLP-1-associated telogen effluvium, a defined subpopulation rather than general telogen effluvium [1]. Any effect observed in that study would therefore be observed in that population specifically [1].
Comparison of evidence types across the two sources
| Source | Evidence type | Population / model | Compound class |
|---|---|---|---|
| [1] | Registered open-label clinical study, 120-day supplement use | Women with GLP-1-associated telogen effluvium | Dietary supplement |
| [2] | Commentary on pharmacovigilance safety signals | Patients on GLP-1RAs and dual GIP/GLP-1RAs | Incretin-mimetic peptides |
Where the evidence is not animal-only or in vitro
Both sources in this evidence block concern human contexts: a registered clinical study in women [1] and a commentary on patient safety signals and prescribing [2]. No animal-only or in vitro data are supplied in the evidence block, and none are asserted here.
If you are reading this for personal health reasons
The materials described here are sold for laboratory research use only. We do not provide dosing, administration, or medical guidance of any kind. Anyone considering a compound for themselves should speak to a licensed clinician.